We used genetic strategies which have been proven valuable to decipher signaling pathways in comparatively simple organisms such as Drosophila and Caenorhabditis elegans, to dissect signaling network activated by tyrosine kinases in mammals. The strategy was developed further towards a generally applicable expression cloning system to identify signal transducers in tyrosine kinase pathways. This system is based on the ability of downstream acting genes to rescue the transformation phenotype of partial loss-of-function mutants of BCR-ABL which still retain tyrosine kinase activity. Using this strategy we have previously shown that overexpression of c-Myc and Cyclin D1 can rescue a signaling defective SH2 mutant of BCR-ABL for transformation. In an unbiased approach to identify new compensating genes, a cDNA library was introduced by retroviral infection into fibroblasts which express the BCR-ABL SH2 mutant. CDNA clones, capable of rescuing the SH2 mutant for transformation should result in colony formation in soft agar. A PCR approach was used to recover these compensating genes from the genomic DNA of the transformed fibroblasts. Sequencing analysis of the initial cDNAs identified three known genes, the adapter molecule Shc, the kinases SPRK and p38 MAPK. These genes have been found to interact functionally with BCR-ABL for fibroblast and hematopoietic cell transformation. Currently, we are constructing and screening new libraries to identify novel genes which complement the BCR-ABL SH2 mutant. Our results demonstrate that this cloning approach is an effective means of identifying and characterizing signaling molecules that function in specific signaling pathways. This in turn may identify specific targets for mechanism-based therapeutic intervention to block altered signaling.
organisms is very complex. Genetic studies in comparatively simple organisms like Drosophila melanogaster and Caenorhabditis elegans are powerful tools to unravel this complexity. 3 One example is the genetic dissection of receptor tyrosine kinase signaling pathways which has revealed a set of cytoplasmatic components from the receptor to mitogenactivated protein kinase (MAPK 4 ). It was believed that this pathway is linear, saturated and highly conserved during evolution. However, using a genetic screen two new genes, daughter of sevenless (Dos 5, 6 ), and kinase suppressor of Ras (Ksr 7 ) have been identified in this pathway. Both genes have been identified as mutated forms that suppress the rough phenotype of the eye in Drosophila. The rough eye phenotype is a consequence of expression of activated mutants along the sevenless receptor tyrosine kinase/Ras/MAPK signaling pathway. Mutations in Dos suppress signaling of an activated sevenless receptor but not activated Ras or Raf. Furthermore, a mutated sevenless receptor which cannot bind its direct connector to the Ras pathway, downstream of receptor tyrosine kinase (Drk), still requires Dos for signal transduction. Mutations in Ksr suppress signaling of an activated Ras allele but not Raf. Since Ras is well documented as interacting directly with Raf, it is highly unlikely that Ksr could be linking Ras to Raf in a linear sequence. These findings lead to a new appreciation of the Ras/MAPK pathway because it is likely more complex than previously assumed. Neither the functions of Dos nor of Ksr can be explained with a linear pathway from tyrosine kinase to the effector molecule. Instead their functions indicate the existence of a complex signaling network. [5] [6] [7] Another example in the appreciation of increased complexity of signaling is the function of Drosophila Jun in fly development. Bohmann's group 3 showed, using a genetic approach, that DJun is regulated by two separate MAPK signal transduction pathways and has different redundant and nonredundant functions. In dorsal closure, DJun has a non-redundant function and is regulated by Hemipterous (Hep) and Basket (Bsk) homologs of JNKK and JNK, respectively. On the other hand, in eye and wing development DJun participates in a separate signaling pathway that is comprised of Ras, Raf and the ERK-type kinase Rolled. In contrast to the strict requirement for Jun in dorsal closure, its role in the eye is redundant.
Both examples prove that genetic approaches are extremely useful in analyzing the function of a given signaling molecule as well as in identifying new signal transducers. Therefore it may be assumed that adaptation of genetic approaches to mammalian systems will lead to a more complete understanding of the even more complex signaling network in these organisms.
A genetic strategy to dissect signaling networks in mammals
We and others [8] [9] [10] [11] [12] have developed a genetic strategy to dissect signaling networks activated by tyrosine kinases in mammals. Based on this approach an expression cloning system was developed to identify new signal transducers in tyrosine kinase signaling pathways. Our idea was to submit partial lossof-function mutants of an oncogenic tyrosine kinase to testing for rescue of the wild-type phenotype by increasing the gene dosage of a regulator or effector molecule. The hypothesis was that increasing the gene expression of effectors compensates for the loss of a specific component or reduced strength of the tyrosine kinase signal.
Signaling by the BCR-ABL tyrosine kinase oncogene
The BCR-ABL tyrosine kinase oncogene is an example of a kinase that activates multiple signaling pathways. 9 BCR-ABL is the result of a reciprocal translocation of chromosome 9 and 22, which results in the fusion of two cellular genes encoding BCR and ABL. 13 The resulting fusion gene encodes an activated protein tyrosine kinase.
14 Two fusion proteins are detected in nature, p210 and p185 BCR-ABL. In general, p210 is associated with chronic myelogenous leukemia (CML) and p185, which exhibits higher tyrosine kinase activity compared to p210, is associated with the more aggressive acute lymphocytic leukemia (ALL 13 ). BCR-ABL is a complex molecule with multiple functional domains, including a BCR oligomerisation and Src homology 2 (SH2)-interacting region, ABL-derived SH2 and SH3 domains, a tyrosine kinase domain, and an actin-binding region at the carboxyl terminus. 15 The BCR sequences activate ABL kinase activity, which is the most critical determinant of transforming activity. [16] [17] [18] Multiple BCR-ABL substrates and binding proteins have been identified (Figure 1 
15
). Some of them have been found to couple BCR-ABL to multiple signaling pathways. These proteins include: (1) Grb-2, which links BCR-ABL to the Ras pathway. [19] [20] [21] [22] (2) CRKL, which also may link BCR-ABL to the Ras pathway, [23] [24] [25] and is in a multimeric complex with PI3-K, c-ABL and BCR-ABL. 26 Furthermore, CRKL links BCR-ABL to the focal adhesion proteins paxillin and CAS (Crk-associated substrate. 27, 28 ) Therefore, CRKL has the potential role to recruit BCR-ABL to the cytoskeleton. 29 (3) Shc, which also connects BCR-ABL to the Ras pathway, 11, 21 and is in a complex with BCR-ABL and PI3-K. 30 ,31 (4) PI3-K, 32 which interacts with Ras 33 and is upstream of Akt. 34 (5) The 14-3-3 protein, 35 which also interacts with Raf, a serine/threonine kinase required for BCR-ABL transformation. 36 The Ras pathway 22 and the PI3-K/Akt pathway 37 have been shown to be essential for BCR-ABL-induced leukemogenesis. However, for most of the BCR-ABL binding proteins the biological relevance of this physical interaction has not yet been proven.
In order to identify domains of BCR-ABL that are important for transformation by connecting the tyrosine kinase signal to downstream signaling pathways we created partial loss-offunction mutants of this oncogene. 11 Point mutations were generated in one of the major tyrosine autophosphorylation sites of the kinase, 19 in the phosphotyrosine binding site of the SH2 domain, 9 or in the Grb2 binding site in the BCR region. 20, 21 All mutants retained tyrosine kinase activity. 9, 19, 20 It was postulated that every site subjected to mutation, when present in its wild-type form, might connect the kinase activity to different signaling pathways. 15 The major autophosphorylation site of the kinase may provide a docking site for SH2 containing cellular proteins while the SH2 domain of Bcr-Abl binds to phosphotyrosine containing proteins. Tyrosine 177, the Grb2 binding site, activates the Ras pathway by Grb2 binding, recruiting of Sos which leads to Ras stimulation. To test the transforming potential of the mutants, each mutant
Figure 2
Outline of the cloning strategy. For details see text. was cloned into a retroviral vector and introduced into rat-1 fibroblast by retroviral infection. Fibroblasts transformed by wt p185 BCR-ABL lead to colony formation when plated into soft agar. 16 In contrast, the p185 BCR-ABL point mutants fail to transform rat-1 fibroblast. 9, 19, 20 We found that increasing the gene dosage of c-Myc by overexpressing c-Myc with a second retroviral construct or co-expressing c-Myc and the BCR-ABL forms in cis within the same retroviral vector specifically rescues the SH2 mutant for fibroblast transformation. 9 The ability of c-Myc to differentially rescue the BCR-ABL point mutants signifies that at least two different signaling pathways are generated by BCR-ABL, one of which depends on Myc.
One could argue against this interpretation on the premise that the observed rescue just reflects the synergistic effect of overexpressing two weak oncogenes, neither of them strong enough to be independently transforming. The observation that only the SH2 mutant is rescued can then be explained with the assumption that the transforming potential of this particular mutant is higher than the others. However, overexpressing other signaling molecules proved that this is not correct. Overexpression of Dbs, a guanine nucleotide exchange factor (GEF) for small GTP-binding proteins, 38 specifically restored the transforming activity of the Grb2 binding site mutant of BCR-ABL for fibroblast transformation but not the SH2 domain or autophosphorylation site mutant. These data clearly show that this genetic strategy is valuable in deciphering the signaling pathways activated by tyrosine kinases. Considering the specific rescue of the p185 Grb2 binding site mutant with Dbs and the rescue of the SH2 mutant with c-Myc one can conclude that a second pathway, in addition to the Myc-dependent pathway, is dependent on Ras. Interestingly, it has been shown recently with the genetic strategy described above, that the p13-K/Akt pathway feeds at least partially into the Myc dependent pathway. 37 One way to dissect the signaling pathways activated by BCR-ABL in more detail would be to test known signaling molecules for rescue of the different BCR-ABL mutants. One disadvantage of this strategy is that it is biased towards a group of known genes. Furthermore, there are so many possible signal transducers that might play a role in the transformation by BCR-ABL that it is nearly impossible to test them one by one in soft agar assays. Therefore, we developed an expression cloning strategy to identify genes in an unbiased manner as well as to clone new genes that rescue the different BCR-ABL mutants for transformation. 
Retrovirus-mediated expression screening in investigating signaling pathways downstream of BCR-ABL
The overall strategy is outlined in Figure 2 . Rat-1 cells expressing a BCR-ABL signaling defective mutant were infected with a retroviral library. In principle, overexpression of every downstream gene in the complex signaling network induced by BCR-ABL should complement at least one BCR-ABL mutant for transformation. Transformed fibroblasts will grow in soft agar. Colony growth in soft agar can therefore be used as a functional assay to identify a gene that rescues a BCR-ABL mutant. The soft agar colonies can be isolated, expanded in culture and genomic DNA can be prepared. The cDNAs will be recovered by PCR, the PCR products directly sequenced and subcloned for in vitro transcription/translation. Positive clones can be cloned into retroviral vectors for functional analysis.
We developed three different functional assays to measure the transforming potential of BCR-ABL. First, the soft agar assay, which has the advantage that it is quantitative and has a clear read out. This is because every single BCR-ABL mutant shows a negative phenotype. The overexpression of a rescuing S32 gene will therefore lead to a switch in the phenotype resulting in numerous agar colonies. By overexpressing a candidate gene with the different BCR-ABL forms we can determine if the gene rescues more than one of the mutants. If overexpression of the candidate gene rescues only one specific mutant, the gene is in a pathway activated by the mutated domain. If, however, the gene rescues more than one mutant, the gene acts downstream of several signaling pathways. In nature, BCR-ABL is exclusively expressed in hematopoietic cells. 15 One might argue that the transformation of fibroblasts does not reflect the situation in ALL and CML. Therefore, we used secondly a high density bone marrow assay. When murine bone marrow is infected by wild-type BCR-ABL encoding retrovirus and cultured under Whitlock/Witte conditions one observes the outgrowth of transformed pre-B lymphoid cells (10 6 cells/ml) within 16 days. 40 When these cells are grown in culture for more than 12 weeks they lose their dependence on a stromal cell layer for growth and demonstrate a high potency for tumor formation in mice. All three point mutants of BCR-ABL are still capable of transforming hematopoietic cells in vitro. 11 However, their transforming potential is clearly diminished when compared with wild-type p185 BCR-ABL. Cultures transformed with any of the point mutants reach saturation densities with a delay of 3-5 days in comparison to cultures transformed by wild-type p185. 10 Furthermore, the outgrowth of transformed pre-B cells occurs in only 60-70% of the cultures, while all cultures infected with wild-type BCR-ABL show a transformed phenotype. Therefore, we tested if a compensating gene expressed together with a BCR-ABL mutant, can restore the regular time course and frequency of bone marrow transformation in culture by wild-type BCR-ABL. Third, the most stringent and representative test of BCR-ABL oncogenic potential is the ability to cause leukemia in mice. As we have shown previously, cells expressing the SH2 mutant of BCR-ABL form tumors poorly in mice. 11 We concluded that the SH2 domain is most critical for transformation. Also, this system provides an in vivo system to test if a candidate gene rescues the SH2 mutant for tumor formation in mice.
The bioassay
Since the SH2 domain of BCR-ABL is most critical for transformation, we decided to infect a rat-1 fibroblast cell line expressing the SH2 mutant with a retroviral library. Cloning with retroviral vectors is a new and powerful strategy [41] [42] [43] [44] [45] which overcomes most of the technical limitations of traditional cDNA transfection methods. [46] [47] [48] [49] [50] A recent review 51 describes applications, advantages and details of this approach in more detail. Here, we will consider only technical difficulties that occur with the agar assay. These difficulties are the specificity and sensitivity of the assay. Since all of the BCR-ABL mutants are partial loss-of-function mutants they still retain tyrosine kinase activity. Therefore, they still form some 'background' colonies if plated in soft agar. In some experiments the background was as much as 10% of wild-type BCR-ABL. We found that the background correlates with the concentration of fetal calf serum used in the assay and the time period after which the agar assay was assessed. Therefore, we established culture conditions under which the background was almost zero. Under these conditions the number of colonies induced by wild-type BCR-ABL was only reduced twofold. If we plated 10 4 fibroblasts expressing the SH2 mutant of BCR-ABL infected with a retrovirus coding for c-Myc, we would obtain not more than 500 colonies in agar. This reflects a low efficiency in transformation of cells at risk. There is also saturation of the system since we would not observe an increase in colony number even if we plated 10 5 cells at risk. Our initial concern was therefore, whether the agar assay is sensitive enough to screen for single genes in a complex library. We performed a pilot experiment in which cells expressing the SH2 mutant of BCR-ABL were infected with different dilutions of a c-Myc containing retrovirus. An infection with the c-Myc viral stock diluted 1:1000 resulted in 7 ± 3 colonies in agar. Since the original stock had 10 6 infectious particles/ml, the concentration of the virus expressing c-Myc Review S Mahlmann et al S33 was now 10 3 /ml. However, in a complex retroviral cDNA library every single cDNA is far more diluted. To avoid the cDNAs being too diluted to be detectable, we created sublibraries in which the cDNAs were enriched. To create the sublibraries, we electroporated the retroviral vector containing the cDNA into E. coli. The transformed bacteria were plated with a density of 5000/dish. Since the library contained 10 6 recombinants, we plated 200 dishes. The library was not amplified in liquid culture, because these conditions would favor the growth of cells harboring plasmids with small or no inserts. Colonies of each 10 dishes were scraped into LB medium, pooled and plasmid DNA was prepared. In this way, we pooled the plasmid DNA of 5 × 10 4 independent bacterial colonies. Twenty different plasmid pools were generated and were used to create independent retroviral stocks. Using this method we increased the representation of the cDNAs up to 50-fold in every retroviral stock. This step proved to be essential, since we only isolated complementing cDNAs from a library when it was divided into sublibraries but not from the same library not divided into sublibraries. The need to enrich the individual cDNAs clearly depends on the sensitivity of the bioassay used in a specific cloning approach. Since only 5-10% of the transformed fibroblasts lead to colony formation in soft agar, the construction of sublibraries is necessary. If in
Figure 5
Signaling pathways activated by BCR-ABL as defined by genetic tests. For details see text.
a cloning strategy a more sensitive bioassay can be used, for instance, FACS sorting of surface antigens, 45, 51 there might be no need to construct sublibraries.
Identification of Shc, SPRK and p38 MAPK as signal transducers in BCR-ABL-induced signaling pathways
We screened 4 × 10 5 independent clones of a murine pre-B cell library and have identified thus far three cDNAs which can rescue the p185 BCR-ABL mutant for transformation. One cDNA encodes the adapter molecule Shc. 52 We obtained the full length clone of the p52 isoform. The other clones were the kinases SPRK [53] [54] [55] and p38 MAPK. 56 Figure 3 shows a schematic representation of the cDNAs we have identified thus far.
The putative role of Shc in the BCR-ABL-induced signaling network
Previously, we have shown that Shc links BCR-ABL to the Ras pathway. 11 In DAGM cells transformed by wild-type BCR-ABL or any of the mutant forms, including the Grb2 binding site mutant, Shc is tyrosine phosphorylated which is not the case in the parental DAGM cells. Tyrosine-phosphorylated Shc associates with the Grb2 adapter molecule in the transformed
cells. The formation of Shc/Grb2 complexes in BCR-ABL transformed cells occurs without direct BCR-ABL/Grb2 association. Overexpression of Shc rescues the BCR-ABL/Grb2 binding site mutant for fibroblast and bone marrow transformation. 11 These results demonstrate that Shc links BCR-ABL to the Ras pathway without BCR-ABL/Grb2 association. Therefore, it was surprising that Shc, identified in the library screen, rescues the BCR-ABL SH2 mutant, since the SH2 domain activates a pathway involving c-Myc 9 and PI3-K. 37 However, Shc has three major phosphorylation sites, Y317, Y239 and Y240. 57 Recent work indicates that phosphorylation of Y317 is important for Grb2 binding and activation of the Ras pathway while phosphorylation of Y239/240 activates a different pathway including c-myc. [58] [59] In addition, Shc is in a complex with p85 PI3-K. 30, 31 Our data are consistent with the possibility that overexpression of Shc may rescue the Grb2 binding site mutant of BCR-ABL via a Ras pathway as well as rescuing the SH2 mutant via another pathway on route to cMyc. This may involve PI3-K. 37 The rescue of the different BCR-ABL mutants with Shc is shown in Figure 4a . Shc may play a pivotal role in oncogenic signaling by feeding into multiple pathways. Currently we are testing this by overexpressing different Shc mutants, Y317F and Y239/240F, together with the different BCR-ABL mutants. The putative role of Shc in the BCR-ABL-induced signaling network is schematically represented in Figure 5 .
The putative roles of SPRK and p38 MAPK in the BCR-ABLinduced signaling network
Human SH3 domain-containing proline-rich kinase (SPRK 54 ), also known as mixed lineage kinase-3 ( MLK3 55 ) is a 97 kDa serine/threonine kinase with multiple protein-protein interaction domains, including an SH3 domain, tandem leucine zippers followed by a basic region and a proline-rich region ( Figure 3) . Furthermore, SPRK contains a binding motif for the small GTP binding protein Cdc42. 60 It has been shown recently that SPRK can specifically activate two members of the MAPK family. 61 C-Jun amino-terminal kinase (JNK 62 ), also known as stress-activated protein kinase (SAPK 63 ) and p38 MAPK 56 are activated by SPRK, while ERKs are not. 61 MAPKs are important mediators of signal transduction from the cell surface to the nucleus. 64 While ERKs are in the pathway mediating cell proliferation in response to growth factors, 65, 66 SAPK and p38 MAPK mediate signals in response to cytokines and environmental stress. 67 SPRK phosphorylates directly the upstream activators of JNK and p38 MAPK 61 which are SEK1 68 and MKK3/6, 69,70 respectively. With SPRK and p38 MAPK we have identified two genes which lie in the same pathway ( Figure 5 ).
We cloned a 1 kb fragment of the human 3.562 kb SPRK cDNA. The fragment includes the catalytic domain of SPRK followed by a leucine zipper motif. The N-terminal SH3 domain of SPRK was deleted in the cloned fragment. Both, the SPRK fragment and the full length clone rescued specifically the SH2 mutant of BCR-ABL for transformation ( Figure  3b ). The SPRK cDNA did not rescue the autophosphorylation site or Grb2 binding site mutants of BCR-ABL (data not shown). The rescue with the SPRK fragment was approximately 4-fold stronger than with the full length clone as measured by numbers of colonies in agar. This might be due to the loss of the SH3 domain, a mode of activation similar to that observed with c-ABL. 15 Our data indicate that SPRK activation is not mediated by Ras but is in a pathway downstream of the SH2 domain of BCR-ABL. This finding is surprising, since SPRK activates JNK 61 and JNK is downstream of, and dependent upon Ras in BCR-ABL transformation. 71 However, it is conceivable that SPRK and Ras signal in parallel to activate JNK. Loss of Ras activation might then not be compensated by SPRK overexpression. Further experiments are necessary to address this question.
In preliminary co-immunoprecipitation experiments we could not detect direct binding of SPRK to BCR-ABL. Recently, a novel serine/threonine kinase, hematopoietic progenitor kinase 1 (HPK1 72 ) was cloned, which is an activator of SPRK in hematopoietic tissues. Therefore, BCR-ABL might signal via HPK1 to SPRK. Experiments are under way to test this hypothesis. Interestingly, HPK1 binds to the SH3 domain of ABL in vitro. 72 In addition, Cdc42 may activate SPRK. 73 Since Vav is a GEF for Cdc42 73 and Vav is phosphorylated by BCR-ABL, 74 there might be a pathway for SPRK activation which includes Vav and Cdc42. The BCR-ABL-induced signaling pathways, as defined by genetic tests, are shown in Figure 5 . In addition to the functional rescue of the BCR-ABL mutants with SPRK and Shc for fibroblast transformation, we tested both genes for their role in the transformation of bone marrow in vitro. When either of the genes is co-expressed with the SH2 mutant of BCR-ABL in primary bone marrow the outgrowth of transformed pre-B cells is accelerated by 2 days in comparison to the SH2 mutant alone.
Our results demonstrate that this cloning approach is an effective means of identifying and characterizing signaling molecules that are biologically relevant in specific oncogenic pathways.
Further applications of retrovirus-mediated expression screening
The cloning system described is widely applicable and can also be used to identify signaling molecules in other, not transforming pathways. If a phenotype is induced by a specific signaling pathway, then a defect in the activated signaling pathway should abolish the phenotype. Rescuing the defect by introducing genes from a retroviral library should then restore the original phenotype and the rescuing gene can be cloned. For instance, Starr et al 75 have cloned a family of suppressors of cytokine signaling (SOCS) by infecting a murine monocytic leukemic M1 cell line with a retroviral library. The parental M1 cells form colonies in soft agar when no cytokine is present. However, in the presence of interleukin-6 the cell line differentiates into mature macrophages and does not form colonies in agar. Therefore, library-derived cDNAs which inhibit interleukin-6 signaling should lead to colony formation in the presence of IL-6. Indeed, genes encoding members of the SOCS family which may act in a classic negative feedback loop to regulate cytokine signaling were cloned in this way.
Another application is to dissect the signaling pathways activated by the CSF1 receptor. 76 Activation of the receptor leads to proliferation, differentiation, and survival of macrophages. 77 Despite their different biological responses, leukemogenesis induced by BCR-ABL, and proliferation, induced by the CSF1R, both kinases share essential common signal transducers in their signaling pathways. Roussel's group 8, 12 has shown that an autophosphorylation site mutant of the CSF1 receptor can also be rescued by Myc or Cyclin D1 overexpression. Therefore, it would be of substantial interest to analyze whether both tyrosine kinases activate the same signaling pathway or whether new molecules can be identified by the described cloning approach which are specific for one or the other kinase. By infecting NIH 3T3 cells expressing a signaling defective human CSF-1R (Y809F) with a retroviral library Roussel's group 76 identified a cDNA clone that rescues the receptor for proliferation. The cDNA encodes a truncated type 1 phosphatidylinositol 4-phosphate 5-kinase. Overexpression of this truncated enzyme resulted in stabilized CSF1R expression on the cell surface, suggesting a role for PIP5K-Ib in receptor endocytosis.
Our data and the examples cited demonstrate that the retroviral cloning approach is an effective means of identifying and characterizing signal transducers that function in specific pathways. When more of these genes are cloned we might be able to understand in more detail what discriminates a deregulated and oncogenic signaling pathway from physiological cellular signaling. This in turn may provide specific targets for mechanism-based therapeutic interventions to block oncogenic signaling.
